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Abstract
Background: MicroRNAs (miRNAs) have the potential to regulate diverse sets of mRNA targets. In addition, 
mammalian genomes contain numerous natural antisense transcripts, most of which appear to be non-protein-coding 
RNAs (ncRNAs). We have recently identified and characterized a highly conserved non-coding antisense transcript for 
beta-secretase-1 (BACE1), a critical enzyme in Alzheimer's disease pathophysiology. The BACE1-antisense transcript is 
markedly up-regulated in brain samples from Alzheimer's disease patients and promotes the stability of the (sense) 
BACE1 transcript.
Results: We report here that BACE1-antisense prevents miRNA-induced repression of BACE1 mRNA by masking the 
binding site for miR-485-5p. Indeed, miR-485-5p and BACE1-antisense compete for binding within the same region in 
the open reading frame of the BACE1 mRNA. We observed opposing effects of BACE1-antisense and miR-485-5p on 
BACE1 protein in vitro and showed that Locked Nucleic Acid-antimiR mediated knockdown of miR-485-5p as well as 
BACE1-antisense over-expression can prevent the miRNA-induced BACE1 suppression. We found that the expression of 
BACE1-antisense as well as miR-485-5p are dysregulated in RNA samples from Alzheimer's disease subjects compared 
to control individuals.
Conclusions: Our data demonstrate an interface between two distinct groups of regulatory RNAs in the computation 
of BACE1 gene expression. Moreover, bioinformatics analyses revealed a theoretical basis for many other potential 
interactions between natural antisense transcripts and miRNAs at the binding sites of the latter.
Background
Recent transcriptomic efforts have revealed surprisingly
large numbers of non-protein-coding RNAs (ncRNAs) in
mammalian genomes [1-4]. Classes of ncRNAs include
small ncRNAs, such as microRNAs (miRNAs) and small
nucleolar RNAs (snoRNAs), and several thousand long
ncRNAs, including those that form complex interleaved
and overlapping patterns with coding transcripts [5-7].
Natural antisense transcripts (NATs) are endogenous
RNA molecules transcribed from the opposite strand of
other protein-coding or non-protein-coding (sense)
genes. A large-scale cDNA sequencing effort, conducted
by the FANTOM-3 consortium, confirmed and greatly
extended the existence of large numbers of NATs [8]. At
least 1,000 pairs of sense-antisense transcripts were
found well conserved between mouse and human [9].
Recently, we have identified and characterized in detail
one sense-antisense pair, BACE1 (beta-secretase-1) and
its antisense partner BACE1-antisense (BACE1-AS), and
demonstrated a critical role of this non-protein-coding
NAT in Alzheimer's disease [10]. Here, we report evi-
dence that a miRNA, miR-485-5p, is involved in BACE1
post-transcriptional regulation. Together with BACE1-
AS, miR-485-5p has the potential to participate in a
ncRNA network that serves to fine-tune BACE1 protein
output in the nervous system.
The mechanisms by which NATs regulate gene expres-
sion are largely unknown. The natural antisense tran-
script for HIF-1α (hypoxia inducible factor-1α)
destabilizes one splice variant of HIF mRNA and shifts
the balance in favour of the other variant [11,12]. Destabi-
lization of one splice variant takes place by exposing the
AU-rich elements in HIF-1α mRNA following antisense
binding to its 3' UTR [11,13,14]. By contrast, stabilization
* Correspondence: clawah@scripps.edu
1 Department of Neuroscience, The Scripps Research Institute, Scripps Florida, 
130 Scripps Way, Jupiter, FL 33458, USA
Full list of author information is available at the end of the article© 2010 Faghihi et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Faghihi et al. Genome Biology 2010, 11:R56
http://genomebiology.com/2010/11/5/R56
Page 2 of 13of mRNA by covering the AU-rich element has been sug-
gested for an antisense transcript of the Bcl-2/IgH hybrid
gene [15]. We previously demonstrated that BACE1-AS
enhances the stability of the BACE1 sense transcript [10].
Here we show that BACE1-AS prevents miRNA-induced
translational repression and mRNA decay of BACE1
mRNA by 'masking' the binding site for miR-485-5p. We
observed that BACE1-AS and miR-485-5p ncRNAs com-
pete for binding to the sixth exonic region of BACE1
mRNA. Covering the miR-485-5p miRNA-binding site by
BACE1-AS transcripts might eliminate miRNA-induced
translational repression and BACE1 mRNA decay. Con-
sidering the reported effects of miRNAs on mRNA stabil-
ity [16], cytoplasmic sense-antisense RNA duplex
formation can potentially inhibit the interactions
between miR-485-5p and BACE1 mRNA to explain, in
part, the enhancement of BACE1 mRNA stability by
BACE1-AS transcripts.
Results
BACE1-AS masks the binding site of miR-485-5p
miRNAs constitute a class of noncoding regulatory RNA
that functions by binding to target RNAs [17]. We have
conducted a bioinformatics search for miRNA binding
sites in BACE1 mRNA and predicted the presence of a
binding site for miR-485-5p in the sixth exon of BACE1
mRNA. Previously we showed that the same region of
BACE1 mRNA may interact with a natural antisense
transcript, BACE1-AS, and that there is potential for
sense-antisense RNA duplex formation (Figure 1a, b).
Considering RNA duplex formation between BACE1 and
BACE1-AS, we postulated that an additional regulatory
function of BACE1-AS may be 'masking' the miR-485-5p
binding site and thereby blocking the inhibitory effects of
this miRNA on BACE1 translation and mRNA decay
(Figure 1a, b). Some other miRNA target sites were found
in the overlapping region of the BACE1 mRNA; however,
the assigned score and binding energy were not sufficient
to be considered as strong candidates. We selected a
number of these miRNAs, including miR-17-3p, miR-
652, miR-593 and miR-183, and over-expressed these in
our cellular model, with a beta-galactosidase reporter
assay corresponding to BACE1 protein as a read-out (see
below). We found that, unlike miR-485-5p, these miRNAs
were not able to alter BACE1 protein concentrations (Fig-
ure 1c). Although these miRNAs did not pass our valida-
tion studies, we cannot completely exclude potential
interactions between these miRNAs and BACE1 or
BACE1-AS transcripts.
Target site validation by luciferase constructs
To validate the predicted miR-485-5p target site in
BACE1 mRNA, we engineered a miR-485-5p target site
downstream of a luciferase reporter gene. This sequence
corresponds to the predicted target site of miR-485-5p on
BACE1 mRNA. We found that the presence of this target
site is sufficient for luciferase reporter protein reduction
upon miR-485-5p over-expression (Figure 2a). We also
constructed a luciferase reporter with either full comple-
mentary or mismatch target sites for miR-485-5p as posi-
tive and negative controls, respectively. Each one of these
three luciferase constructs was transfected into
HEK293T cells in the presence of miR-485-5p over-
expressing or empty control vectors. We observed signifi-
cant down-regulation of luciferase in the construct with
miR-485-5p target sites in the presence of a miR-485-5p
over-expressing vector. Our results indicate that the pres-
ence of our predicted miR-485-5p target site is sufficient
for miRNA binding, suggesting the possibility of in vivo
interactions between miR-485-5p and its cognate binding
site in the sixth exonic region of the BACE1 mRNA.
Validation of a binding site in the coding region
Although luciferase reporters are extensively utilized as a
validation tool for miRNA targets, these constructs have
limitations for evaluating binding sites located in the cod-
ing region. To create a construct that resembles an in vivo
setting, we cloned full-length BACE1 cDNA, excluding
the 3' UTR, into a ProLabel C3 expression vector (Dis-
coveRx). The ProLabel C3 vector, upon transfection into
mammalian cells, expresses BACE1 mRNA and protein
with a small fusion tag. The protein tag is then used for
the detection of protein synthesis utilizing the enzyme
fragment complementation (EFC) system. Next, we
examined the effect of miR-485-5p over-expression on
BACE1 protein in HEK293T C3 cells using enzyme com-
plementation protein quantification technology (Discov-
eRx). We found that miR-485-5p over-expression causes a
reduction in BACE1 protein concentrations (Figure 2b).
Our results indicate that miRNA-binding sites in the cod-
ing parts of mRNAs may still be functional and further
suggest the possibility of in vivo interactions between
miR-485-5p and mature BACE1 mRNA.
Locked nucleic acid-antimiR blocks miR-485-5p effects on 
BACE1 protein
To test the specificity of the reduction of BACE1 and to
further validate the miR-485-5p target site in the coding
region of BACE1, we applied a synthetic locked nucleic
acid (LNA)-antimiR molecule to block the miRNA bind-
ing. Such antimiRs are synthetic, LNA-modified RNA
molecules with sequence complementary to the mature
miRNA. As expected, over-expression of miR-485-5p
reduced the BACE1 protein levels and this reduction was
blocked by application of LNA-antimiR-485-5p (Figure
3a). We observed that the LNA-antimiR increased
BACE1 protein levels in our EFC reporter assay, which
may possibly be explained by inhibition of endogenous
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Figure 1 BACE1-AS and miR-485-5p competing for the same binding site in BACE1 mRNA. (a) Sequence information of miR-485-5p and its tar-
get site in BACE1 mRNA. Binding site in BACE1 mRNA has a strong affinity to the miR-485-5p (free energy = -26.3 using Microinspector; -31.5 using 
RNA22; -22.8 using miRacle). The predicted target sequence AAGCTGTAGTCAAATCCATCAAGGCAGCCTCC is found within exon 6 of BACE1. (b) The 
schematic shows the predicted target site for miR-485-5p, the BACE1-AS transcript and their relation to BACE1 mRNA. The binding site for miR-485-5p 
is located in the overlapping region of BACE1 and BACE1-AS. BACE1 exons are marked as E1 to E10. Both BACE1-AS and miR-485-5p have the potential 
to bind to exon 6 (E6) of BACE1 mRNA. (c) Over-expression of miR485-5p, but not vectors that over-express miR-17-3p, miR-652, miR-593, or miR-183, 
nor control empty vector, leads to BACE1 protein reduction by about 30% (**P-value < 0.01). Each treatment consists of 24 repeats and error bars rep-
resent standard error of means. In this experiment, the miRNA-binding site was not artificially engineered; rather, it is located in its usual place in the 
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BACE1 protein reduction by LNA-antimiR indicates the
specificity of the miRNA effect and further validates the
miR-485-5p binding site in the coding region of BACE1
mRNA.
Noncoding RNAs compete for binding sites
Considering that BACE1-AS and miR-485-5p share
potential binding sites in the BACE1 mRNA, we aimed to
check the possible counteraction of these two ncRNA
transcripts. If these two ncRNAs can compete for binding
sites, then simultaneous over-expression should block the
effect of miR-485-5p. Indeed, we noted that over-expres-
Figure 2 Validation of the miR-485-5p binding site in the BACE1 
transcript. (a) The presence of the miR-485-5p target site in the 3' UTR 
of firefly luciferase is sufficient for depleting luciferase expression by 
30%, equally effective as a perfect match positive control. The scram-
bled target site did not show any effect (**P-value < 0.01). This experi-
ment was performed in HEK293T cells and each treatment consisted of 
24 biological repeats; error bars represent standard error of means 
(SEM). (b) Over-expression of miR485-5p, but not control miRNA (miR-
219) or empty vector, leads to BACE1 protein reduction by about 30% 
(***P-value < 0.001). Each treatment consists of 32 biological repeats 
and error bars represent SEM. In this experiment, the miRNA-binding 
site was not artificially engineered; rather, it is located in its usual place 
in the open reading frame of the BACE1 transcript. BACE1 protein level 
was measured by DiscoverRx technology.
(a)
(b)
Figure 3 BACE1-AS masks the binding site for miR485-5p on 
BACE1 mRNA. (a) Over-expression (O/E) of miR485-5p significantly re-
duces BACE1 protein levels in HEK293T C3 cells. BACE1 protein was 
measured by EFC protein quantification technology (DiscoveRx). LNA-
antimir-485-5p, a sequence complementary to the mature miR-485-
5p, blocks the effect of miRNA on BACE1 protein expression. LNA-anti-
miR-485 increases BACE1 protein levels by blocking endogenous miR-
485-5p. Each treatment consists of 24 biological repeats and error bars 
represent standard error of means (SEM; **P-value < 0.01 and ***P-val-
ue < 0.001). (b) Simultaneous over-expression of miR-485-5p and 
BACE1-AS can effectively block the observed BACE1 protein reduction 
caused by miR-485-5p alone. This indicates that the two ncRNAs can 
compete for the same binding site on BACE1 mRNA. Each treatment 
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and returned the BACE1 protein to basal levels (Figure
3b). We previously showed that over-expression of
BACE1-AS caused an increase in BACE1 protein level
and we were able to reproduce these data, using our in
vitro EFC assay. On the other hand, we observed that
miR-485-5p over-expression reduced the BACE1 protein
levels. Simultaneous over-expression of both BACE1-AS
and miR-485-5p returned the BACE1 protein level to the
basal level. These data imply that miR-485-5p and
BACE1-AS may compete for binding to BACE1 mRNA
and support the novel regulatory role of masking a
miRNA-binding site in BACE1 by the non-coding
BACE1-AS transcript. This proposed miRNA masking
effect is in concert with the concordant antisense regula-
tory action of BACE1-AS.
Expression of miR-485-5p, BACE1 and BACE1-AS in different 
brain regions
To confirm the expression of BACE1, BACE1-AS and
miR-485-5p in brain and other human tissues, we per-
formed real-time PCR (RT-PCR) on RNA samples from
human and mouse. We observed that miR-485-5p is pres-
ent and significantly higher in brain compared to other
regions (Figure 4a). BACE1 and BACE1-AS transcripts
showed ubiquitous expression patterns with minimal
variation among different tissues. Similar results were
observed in mouse tissues and various regions of mouse
brain showed high expression of miR-485-5p, BACE1 and
BACE1-AS transcripts (Figure 4b). The high concentra-
tion of miR-485-5p and BACE1-AS in the brain regions
suggests the likelihood of their functional interaction
with the BACE1 mRNA target site, and involvement in
BACE1 regulation.
Next, we examined the expression of BACE1, BACE1-
AS and miR-485-5p in four brain regions from human
control subjects (Figure 4c). These RNA samples origi-
nated from post-mortem brains of 35 elderly individuals
with an average age of 72.3 years (range 53 to 91 years)
who had passed away from causes other than Alzheimer's
disease. Although not all regions were available from all
cases, we examined RNAs from cerebellum (18 subjects),
entorhinal cortex (8 subjects), hippocampus (12 subjects)
and superior frontal gyrus (18 subjects). Unlike BACE1-
AS, miR-485-5p was two- to four-fold higher in entorhi-
nal cortex, hippocampus and superior frontal gyrus com-
pared to cerebellum. BACE1-AS transcript was expressed
two- to three-fold lower in similar regions compared to
cerebellum. It is worth noting that the transcript expres-
sion data represent the relative quantity of each RNA
transcript to that of reference tissue (brain in Figure 4a,
and cerebellum in Figure 4b, c). Therefore, these data do
not directly support the conclusion that expression of
miR-485-5p represses BACE1 transcript levels and that
BACE1-AS expression enhances BACE1 transcript levels.
Nevertheless, the relatively high expression of miR-485-
5p and BACE1-AS in brain regions that are affected by
Alzheimer's disease pathology may suggest a role for
these ncRNAs in Alzheimer's disease-related pathogene-
sis.
miR-485-5p expression as studied by high-throughput 
sequencing
We also examined the abundance of miR-485-5p in vari-
ous human tissues by next generation sequencing of the
small RNA fraction, using the Illumina Genome analyzer.
Two individuals were used for sequence profiling of the
small RNA fraction and identification of known miRNAs
from a set of eight tissues. We found that the number of
normalized reads for miR-485-5p was significantly higher
in the orbital gyrus from brain compared to skeletal mus-
cle, pancreas, lung, heart, liver, spleen and kidney (Figure
4d). The raw read count for miR-485-5p differed between
the two individuals as follows: pancreas, 1.5%; lung, 1.6%;
skeletal muscle, 1.5%; heart, 1.25%; brain, 1.4%; liver,
3.5%; spleen, 8.6%; and kidney (only one sample). The
normalized reads from deep sequencing experiments
provide absolute quantities, in contrast to relative quan-
tity values obtained from RT-PCR methods. Therefore,
the high expression of miR-485-5p in orbital gyrus of
brain revealed by deep sequencing data confirms our RT-
PCR findings. Moreover, the substantial abundance of
miR-485-5p in the brain, compared to other tissues, sug-
gests a neuronal-related function, and by reason of co-
expression, increases the likelihood of involvement in
BACE1 regulation.
Expression of BACE1, BACE1-AS and miR-485-5p in 
Alzheimer's disease
We previously showed that the BACE1-AS transcript is
significantly up-regulated in several brain regions of sub-
jects with Alzheimer's disease. We measured the expres-
sion of BACE1, BACE1-AS and miR-485-5p in two
different sets of RNA samples from control subjects and
individuals with Alzheimer's disease. Initially, we exam-
ined the parietal lobe and cerebellum of 5 subjects with
Alzheimer's disease and 5 normal elderly individuals (20
samples total). BACE1-AS, and to a lesser degree BACE1,
transcripts were up-regulated in Alzheimer's disease
patients compared to control individuals and miR-485-5p
was down-regulated by 30% in parietal lobe and close to
60% in cerebellum of Alzheimer's disease patients (Figure
5a).
We have also examined a second set of RNA samples
from 35 Alzheimer's disease and 35 control individuals
(Figure 5b). Although not all regions were available from
all cases, we examined RNA from cerebellum (18 control
and 23 Alzheimer's disease subjects), entorhinal cortex (8
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Figure 4 Expression of BACE1, BACE1-AS and miR-485-5p in different brain regions. (a) Expression of miR-485-5p, BACE1 and BACE1-AS were 
measured in a commercially available panel of human tissues (n = 1), including brain, liver, heart, skeletal (Sk) muscle, spleen, kidney, testis and lung, 
by RT-PCR. Whole brain RNA shows a much higher abundance of miR-485-5p (y-axis is log2% of brain). BACE1 mRNA was ubiquitously expressed, with 
the highest expression in brain. BACE1-AS transcript was expressed in all tissues, but relatively higher in brain, heart, skeletal muscle and testis. (b) Ex-
pression of miR-485-5p, BACE1 and BACE1-AS transcripts were measured in several mouse brain region as well as mouse liver (n = 3). miR-485-5p is 
readily present in various brain regions, but it is not evenly distributed in all regions tested. BACE1 and BACE1-AS transcripts are also highly expressed 
in all brain regions that are affected by Alzheimer's disease pathologies. (c) Expression of miR-485-5p, BACE1 and BACE1-AS transcripts were measured 
in four human brain regions. RNA originated from cerebellum (18 subjects), entorhinal cortex (8 subjects), hippocampus (12 subjects) and superior 
frontal gyrus (18 subjects). miR-485-5p was two- to four-fold higher in entorhinal cortex, hippocampus and superior frontal gyrus compared to cere-
bellum. BACE1-AS transcript was expressed two- to three-fold lower in entorhinal cortex, hippocampus and superior frontal gyrus compared to cere-
bellum. BACE1 mRNA is almost equally distributed in all four regions. (d) The small RNA fraction from two individuals for each of eight tissues (with the 
exception of the kidney, which had only one sample) was used for high-throughput short read sequencing. After alignment of reads to the human 
genome, the reads corresponding to miR-485-5p were identified and normalized to the total number of reads. There was significantly higher abun-
dance of miR-485-5p in the orbital gyrus of the brain compared to skeletal muscle, pancreas, lung, heart, liver, spleen and kidney.
(a) (b)
(c) (d)
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Figure 5 Expression of BACE1, BACE1-AS and miR-485-5p in Alzheimer's disease-affected individuals. (a) Expression of BACE1, BACE1-AS and 
miR-485-5p transcripts were measured in parietal lobe and cerebellum of five subjects with Alzheimer's disease and five normal elderly individuals. 
miR-485-5p was down-regulated by 30% in parietal lobe and 60% in cerebellum of Alzheimer's disease patients compared to control individuals. 
BACE1-AS as well as BACE1 transcripts were up-regulated in both cerebellum and parietal lobe (unpaired t-test with Welch's correction: ns = not sig-
nificant; *P-value < 0.05; **P-value < 0.01; ***P-value < 0.001). (b) Expression of BACE1, BACE1-AS and miR-485-5p transcripts were measured in four 
regions of the brain of 35 Alzheimer's disease patients and 35 control individuals. Not all regions were available from all cases; a total of 120 RNA sam-
ples from superior frontal gyrus, entorhinal cortex, hippocampus and cerebellum were tested. miR-485-5p was significantly down-regulated in ento-
rhinal cortex and hippocampus of Alzheimer's disease subjects, but not altered in cerebellum nor in superior frontal gyrus. BACE1-AS, and to a lesser 
degree BACE1, transcripts were up-regulated in all four regions. However, the increase in BACE1 mRNA was not statistically significant in cerebellum 
and hippocampus (unpaired t-test with Welch's correction: ns = not significant; *P-value < 0.05; **P-value < 0.01; ***P-value < 0.001)
(a)
(b)
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Page 8 of 13control and 11 Alzheimer's disease subjects), hippocam-
pus (12 control and 12 Alzheimer's disease subjects) and
superior frontal gyrus (18 control and 18 Alzheimer's dis-
ease subjects). Consistent with our previous work,
BACE1-AS transcript concentrations were up-regulated
in all four regions tested. To a lesser degree, BACE1 tran-
scripts were up-regulated in entorhinal cortex as well as
in superior frontal gyrus. On the other hand, miR-485-5p
was significantly reduced in entorhinal cortex and hip-
pocampus. However, miR-485-5p was not significantly
altered in cerebellum and superior frontal gyrus (Figure
5b). The difference between miR-485-5p expressions in
cerebellum of the two sets of RNA samples can conceiv-
ably be explained by the relatively high variability among
human samples. Considering the increased level of
BACE1-AS and reduction of miR-485-5p in the brain of
Alzheimer's disease subjects, we postulated that dysregu-
lation of these two ncRNAs might cause increases in
BACE1 mRNA as well as the removal of the miRNA
brake on BACE1 mRNA and protein expression.
miRNA binding site enrichment in non-overlapping regions 
of sense-antisense pairs
Our data suggest an interaction between two classes of
ncRNAs in the regulation of BACE1 gene expression. We
sought to determine the extent of this computational reg-
ulatory mechanism as a general theme in the human
genome. We selected a set of evolutionarily conserved
sense-antisense pairs, previously published as complex
loci in human and mouse genomes [9]. Predicted miRNA
binding sites within pairing (sense-antisense overlapping)
regions and non-pairing (non-overlapping) regions were
counted and are listed in Additional file 1. In summary,
among 894 sense-antisense pairs included in this study,
391 (43.7%) contain a sense-antisense overlapping region
equal to or more than 25 nucleotides, which were
selected for further miRNA binding-site scanning. A total
of 18,704 predicted miRNA binding sites were identified
in the sense-antisense pairing regions, spanning 358,663
nucleotides. In non-pairing regions, 111,192 miRNA
binding sites were predicted across 1,570,606 nucleotides.
After normalization of the predicted miRNA targets over
sequence lengths, the miRNA binding sites within sense-
antisense pairing regions ranged from 0 to 0.18790 miR-
NAs per nucleotide, with an interquartile range of
0.01398 to 0.08620, and a median value of 0.04780 miR-
NAs per nucleotide. The miRNA binding sites within
non-pairing regions range from 0 to 0.2173, with an
interquartile range of 0.03350 to 0.10020, and median
value of 0.06490 miRNAs per nucleotide. There are more
predicted miRNA binding sites in non-overlapping
regions of the sense-antisense pairs compared to overlap-
ping regions (P-value < 0.0001, Wilcoxon test). On aver-
age (mean), each 100 nucleotides of overlapping region
have 5.21 miRNA binding sites, while each 100 nucle-
otides of non-overlapping region have 7.07 miRNA bind-
ing sites (Figure 6). This result was corroborated by our
randomization test (P-value < 0.0001), in which 1,000
Monte Carlo randomizations with shuffled sequences
were carried out. Our result indicates an evolutionary
selection against miRNA binding to the pairing region.
These findings suggest that overlapping regions between
sense and antisense RNA transcripts are functional regu-
latory elements per se, and that sense-antisense RNA
duplex formation may prevent miRNA binding. There-
fore, there might be a selection to avoid a clash of two
regulatory elements in one particular region.
Discussion
Normal physiological levels of BACE1 protein are essen-
tial for proper cognitive, emotional and synaptic function
[18], and for myelination of peripheral nerves [19,20]. On
the other hand, elevation of BACE1 protein might cause
overproduction of amyloid peptides, such as amyloid-β 1-
42 (Aβ1-42) and Aβ1-40. Imbalance between production
and clearance of Aβ1-42 could potentially lead to the cas-
cade of amyloid precursor protein cleavage, amyloid
plaque formation, and the synaptic disruption character-
Figure 6 Distribution of miRNA binding sites in sense-antisense 
RNA transcripts. Predicted miRNA binding sites were counted in 391 
human sense-antisense pairs. The total number of predicted miRNAs 
per 100 nucleotides of overlapping and non-overlapping regions of 
each sense-antisense pair is depicted. The miRNA binding sites within 
pairing and non-pairing regions have a median value of 4.78 and 6.49 
miRNAs per 100 nucleotides, respectively. On average (mean), each 
100 nucleotides of overlapping region have 5.21 miRNA binding sites, 
while each 100 nucleotides of non-overlapping region have 7.07 miR-
NA binding sites. The difference seen in miRNA numbers within the 
sense-antisense pairing regions and non-pairing regions is statistically 
significant (***P-value < 0.0001, Wilcoxon two-sided test).
Faghihi et al. Genome Biology 2010, 11:R56
http://genomebiology.com/2010/11/5/R56
Page 9 of 13istic of early Alzheimer's disease. The levels of BACE1
therefore require tight regulation to maintain a narrow
window between essential and pathological expression of
BACE1. Sequential cleavage of amyloid precursor protein
by BACE-1 and γ-secretase represents a central event in
Alzheimer's disease pathophysiology, and both proteases
serve as potential targets for development of novel thera-
peutics for Alzheimer's disease [21]. Thus, understanding
the mechanisms of BACE1 regulation may reveal impor-
tant insights into the etiology of Alzheimer's disease, and
also facilitate the development of novel therapeutics and/
or biomarkers of the disease [22-25].
We have previously demonstrated that BACE1-AS
enhances the stability of the BACE1 sense transcript [10].
In this study, we show an additional, synergistic mecha-
nism by which BACE1-AS regulates its sense partner,
namely by preventing miRNA-induced mRNA decay and
translational repression. Specifically, miR-485-5p and
BACE1-AS likely share a common binding site in the
sixth exon of the BACE1 mRNA transcript. Therefore,
interactions between either one of these two ncRNAs and
BACE1 mRNA would establish a finely tuned regulation
of BACE1 protein production. Destabilization of mRNA
after miRNA binding has been previously suggested [16].
We hypothesized that one mechanism by which BACE1-
AS regulates BACE1 mRNA stability involves the 'mask-
ing' of a miR-485-5p binding site. Hence, the translational
repression and destabilization of BACE1 mRNA by miR-
485-5p is less likely to occur in the presence of the
BACE1-AS transcript. Nonetheless, both proposed
actions of BACE1-AS, promoting target mRNA stability
by duplex formation and inhibiting miRNA-induced
mRNA decay and translational repression, serve to ele-
vate BACE1 concentrations.
Alzheimer's disease patients demonstrate increased
expression of BACE1 mRNA and generation of Aβ1-42
compared with unaffected controls [26-30]. Our data
suggest that BACE1-AS and miR-485-5p are both highly
expressed in the nervous system. The dysregulation of
these two ncRNA transcripts may induce Alzheimer's
disease-related BACE1 upregulation by stabilizing the
BACE1 transcript and by blocking miRNA-induced
translational repression. Interplay between these ncRNAs
might be crucial for neuronal cells to maintain a precise
physiological BACE1 homeostasis involving post-tran-
scriptional regulatory mechanisms.
Disruption of miRNA binding sites by the presence of
SNPs in the 3' UTRs of mammalian genes has been
clearly documented [31-35]. Variants in the binding site
for miR-189 in the 3' UTR region of the SLITRK1 gene
are associated with Tourette's syndrome [35]. Synony-
mous mutations in regulatory regions of mRNAs could
create or destroy a putative miRNA binding site, there-
fore changing the protein output of specific transcripts
[31]. The SNP in the 3' UTR of the myostatin gene
(GDF8) that creates a target site for miR-1 and miR-206
contributes to the muscular hypertrophy of Texel sheep
[31]. Additionally, the variant allele in a KRAS mRNA,
associated with a Let-7 miRNA complementary site, is
significantly linked with an increased risk for lung carci-
noma [32]. A functional SNP at a miRNA binding site
(miRSNP) in the 3' UTR of dihydrofolate reductase inter-
feres with miR-24 function and leads to dihydrofolate
reductase over-expression and methotrexate resistance
[33,34]. These examples point to the fact that any inter-
ference between miRNAs and their binding sites would
have regulatory consequences. We argue here that cyto-
plasmic natural antisense transcripts bind to sense
mRNA and 'mask' miRNA binding sites. We think that
the cytoplasmic sense-antisense RNA duplex formation is
transient and reversible, as a stress response would
require; therefore, interactions between sense mRNA,
antisense transcript and miRNA might determine the
level of protein production. In line with this hypothesis,
we present evidence to show in vitro competition
between miR-485-5p and BACE1-AS for binding to
BACE1 mRNA. This novel masking function for the anti-
sense RNA may apply to many other natural antisense
transcripts.
The effect of miR-485-5p on BACE1 may demonstrate a
non-canonical miRNA target site in the coding region of
a mammalian mRNA, overlapping with the site of sense-
antisense duplex formation. In contrast with plant miR-
NAs, most animal miRNAs are predicted to have their
binding site in 3' UTR of target mRNA [36]. Although
most web prediction tools for miRNA binding sites are
designed to search only for 3' UTR regions of transcripts,
there is no evidence against miRNA binding to the coding
region. Binding of miRNA to the coding region of
mRNAs, or even the 5' UTR, has been shown in plants
and recently in animals [37-40]. Our results further sug-
gest that miRNA association with any position on a target
mRNA is mechanistically sufficient for binding.
In our bioinformatics study, we showed that miRNAs
are predicted to target the non-overlapping region of
sense-antisense RNA transcripts, outside of the genomic
regions that have the potential to form sense-antisense
duplex formation. This strategy might be beneficial from
an evolutionary point of view, enabling the antisense
sequences and the miRNAs to exert fine-tuned regula-
tory roles through targeting different sites on the same
target mRNAs. The fact that there are fewer predicted
miRNA binding sites in the overlapping region of natural
antisense transcripts suggests that gene regulation, for
both RNA species, takes place by ncRNA-mRNA nucle-
otide complementarities, and further suggests that both
groups are functional regulatory elements. In this con-
text, competition between these two regulatory elements,
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tions that would allow a more complex type of regulation.
This complex regulatory architecture, combined with its
evolutionary conservation, suggests a profound biological
importance for the BACE1-AS-mediated stress response,
including a biological function for the transient increase
in Aβ levels that occur as a result of the regulatory action
of these ncRNAs.
In fact, the stress response of the BACE1 sense-anti-
sense locus involves additional elements of complexity
[10]. In contrast to the BACE1 sense transcript, the
BACE1-AS transcript shows a pronounced nuclear
enrichment pattern, similar to other nuclear-enriched
ncRNA transcripts [41]. We previously documented that
the stress responsive BACE1-AS transcript shifts into the
cytosol upon exposure to neuronal stress, contributing to
a rapid but reversible increase of BACE1 protein, and Aβ
production [10]. Emerging data suggest that miRNAs and
NATs are both instrumental in a variety of stress
responses [42,43]. A synergy between these two classes of
ncRNAs as we have hypothesized here is an intriguing
possibility that would significantly increase the regula-
tory power of these families of ncRNAs within the con-
text of a larger ncRNA sensory and regulatory network
[44]. These mechanisms, together with the unusual but
specific response of the BACE1 system to stress, may
explain some aspects of Alzheimer's disease and other
neuropathologies related to chronic stress response.
Different cell stressors, such as hypoxia, re-oxygen-
ation, oxidative stress and some pro-apoptotic factors,
have long been implicated in the pathogenesis of
Alzheimer's disease. These stressors are known to
enhance BACE1 activity and Aβ1-42 production, which
likely contributes to Alzheimer's disease pathophysiology
[45,46]. Also, there is considerable evidence that Aβ1-42
itself is a potent cell stressor [47-49]. Further, Aβ1-42
enhances BACE1 mRNA and protein activity, and can
thereby cause damage to neurons through various cell-
stress-related mechanisms [47]. We have recently shown
that a variety of cell stressors can increase BACE1-AS and
BACE1 expression, therefore enhancing Aβ1-42 biosyn-
thesis [10]. Since BACE1-AS regulates BACE1 in vivo, we
propose that the elevation of BACE1-AS as a result of the
actions of Alzheimer's disease-related cell stressors forms
a basis of a deleterious feed-forward cycle of disease pro-
gression. This deleterious effect of BACE1-AS may, at
least in part, come from the ability of this transcript to
mask a miR-485-5p binding site. The increase in BACE1
protein by removing the negative effect of miRNAs might
then contribute to enhanced Aβ1-42 formation and for-
mation of amyloid plaques. It should be noted that Aβ1-
42 accumulation in the Alzheimer's disease brain is a
long-lasting and chronic process and that even small
changes in BACE1 activity may lead to a significant
increase in amyloid deposition over time [50,51].
Conclusions
Our data demonstrate a potential competition between
two different classes of ncRNAs. We present evidence to
show that miR-485-5p and BACE1-AS transcripts com-
pete for a binding site in the sixth exonic region of BACE1
mRNA. We show that the expression of BACE1-AS as
well as miR-485-5p is dysregulated in RNA samples from
Alzheimer's disease subjects compared to age and sex
matched control individuals. Moreover, we show that
over-expression of miR-485-5p and BACE1-AS has
opposing regulatory effects on BACE1 protein expres-
sion. These data, along with our previous findings, indi-
cate a ncRNA regulatory network exerting control over
the expression of BACE1 and further provide an addi-
tional mechanism of NAT-mediated regulation of BACE1
mRNA. Our findings thus support the existence of
ncRNA-containing regulatory networks that may be
implicated in Alzheimer's disease pathophysiology.
Materials and methods
RT-PCR
RT-PCR was carried out with the GeneAmp 7900
machine (Applied Biosystems, Foster City, CA, USA).
The primers and probe for miR-485-5p were bought from
Applied Biosystems. The primers and probe for BACE1
and BACE1-AS were previously reported [10]. The PCR
conditions were as follows: 50°C for 2 minutes then 95°C
for 10 minutes then 40 cycles of 95°C for 15 s and 60°C for
1 minute. The results are based on cycle threshold (Ct)
values. Differences between the Ct values for experimen-
tal and reference genes (Human beta-actin or U6 small
RNA) were calculated as ΔΔCt.
High-throughput sequencing
Sequencing was carried out on RNA from two individuals
for eight tissues, pancreas, lung, heart, skeletal muscle,
brain, liver, spleen and kidney (kidney had only one sam-
ple). Sequencing was carried out using the Illumina
genome analyzer. Small RNA libraries were prepared and
36 cycle sequencing carried out according to the manu-
facturer's instructions. Briefly, total RNA was fraction-
ated and the 18-35 nucleotide fraction isolated. RNA
adapters were ligated to the 3' and 5' ends of the samples
and used for cDNA synthesis. Libraries were sequenced
on the genome analyzer (Illumina, San Diego, CA, USA)
and the sequences analyzed using miRanalyzer [52]. The
number of unique reads for miR-485-5p were counted for
each tissue and normalized to the total number of reads.
The short read sequence data were submitted to the
Sequence Read Archive at the National Center for Bio-
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SRA012516.1 and is freely available.
Cell culture and transfection
HEK293T cells were cultured in DMEM plus 10% fetal
bovine serum and transfected with BACE1-AS, miR-485-
5p, other miRNAs or empty vectors.
Statistical analysis
All experiments were performed with at least three to six
biological and technical repeats. Beta-galactosidase and
luciferase studies were performed in 96-well plates with
at least 24 replicates for each treatment. The data are pre-
sented in graphs as a comparison with controls, after post
hoc test of treatment factor using main effect in two-way
analysis of variance (ANOVA). Alternatively, an unpaired
t-test with Welch correction was used to calculate signifi-
cance of the differences. The significance of each treat-
ment was calculated as a P-value and is reported in the
legend of each figure; P < 0.05 was considered significant.
Enzyme complementation assay (DiscoveRx)
ECA is a technology developed by DiscoveRx (Fremont,
CA, USA) that allows the measurement of changes in
protein levels. The cDNA of BACE1 was cloned into
pCMV-ProLabel vector upstream of the ProLabel and
transfected into HEK293T cells to produce a fusion pro-
tein (BACE1 and the enzyme donor fragment) expressed
in a stable cell line we call C3. When the two fragments
(enzyme donor and enzyme acceptor) of the β-galactosi-
dase combine in solution, the enzyme becomes active and
hydrolyzes a substrate that produces a chemiluminescent
signal. The strength of this signal is proportional to the
protein being produced (in this case BACE1). The stable
cell line C3 over-expressing BACE1 was transfected with
BACE1-AS over-expression vector, miRNA over-expres-
sion vector or control vectors and protein expression
measured 48 hours later with the DiscoveRx method;
data are plotted as a percentile of control vector.
Luciferase and miR-485-5p over-expression 
experiments
The predicted target site of miR-485-5p on BACE1
mRNA was engineered into the 3' UTR of a firefly
luciferase construct; as a positive control we used a per-
fect match to miR-485-5p, and as a negative control we
used a scrambled target site inserted downstream of fire-
fly luciferase. LNA-antimiR for miR-485-5p was pur-
chased from Exiqon (Exiqon, Vedbaek, Denmark) and
transfected at 10 nM concentration. The firefly luciferase
construct along with a renilla luciferase construct (Prltk,
Promega, WI, USA) and miRNA over-expression vectors
were transfected into HEK293T cells in 96-well plates.
Luciferase activity was assessed 48 hours later and firefly
luciferase expression normalized to the renilla and
graphed as a percent of controls. Alternatively, miRNA
over-expression vectors (with pre-miRNA constructed
into the pMSCV vector; kindly provided by Dr Corinne
Lasmezas) - miR-485, miR-219 as a control or empty vec-
tor - were transfected into the HEK293T C3 cell line
(ProLabel, DiscoveRx) and protein quantification was
performed using DiscoveRx technology.
Human samples
The first set of human brain samples was prepared at the
USC Alzheimer's Disease Research Center, which
obtained informed consent from all subjects; the USC
Institutional Review Board then approved the use of the
human tissues. RNA was extracted from parietal lobes
and cerebellum of postmortem brains from five subjects
with Alzheimer's disease and five matched controls. The
average age of subjects with Alzheimer's disease was 85
years (range 75 to 92 years) and 91.8 years (90 to 95 years)
for controls. The postmortem interval ranged from 3.75
to 10.1 h with a mean of 5.87 h. We treated RNA samples
with DNase and purified them with RNeasy mini col-
umns (QIAGEN Valencia, CA, USA). We prepared cDNA
from 400 ng of RNA samples and used RT-PCR for rela-
tive quantification of different transcripts.
The second set of human brain samples and the tissues
used for deep sequencing were prepared from rapid
autopsy brain tissue and were collected by J Rogers and T
Beach (Sun Health Research Institute); all enrolled sub-
jects or legal representatives had signed a Sun Health
Research Institutional Review Board-approved informed
consent form allowing both clinical assessments during
life and several options for brain and bodily organ dona-
tion after death. These cases included 35 autopsy con-
firmed cases of Alzheimer's disease with an average age of
81.8 years (range 64 to 92 years) and 35 controls with an
average age of 72.3 years (range 53 to 91 years). The post-
mortem interval ranged from 1.25 to 5 h with a mean of
2.5 h. The average duration of disease in the subjects with
Alzheimer's disease was 9.2 years. Total RNA was iso-
lated via CsCl purification from tissue dissected from
specific regions of brain. Although not all regions were
available from all cases, we examined a total of 120 RNA
samples from superior frontal gyrus, entorhinal cortex,
hippocampus and cerebellum for BACE1, BACE1-AS and
miR-485-5p expression by RT-PCR.
A panel of total RNA from human tissues was bought
from Applied Biosystems and used for expression profil-
ing of BACE1, BACE1-AS and miR-485-5p.
Bioinformatics detection of miRNA binding sites
Published human miRNA sequences were retrieved from
the miRBase database [53]. A list of 993 evolutionarily
conserved natural antisense transcripts was retrieved
from the previously published FANTOM-3 dataset [9].
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described in this study, as we could not verify that they
indeed qualify as sense-antisense pairs. miRNAs were
screened in the sense-antisense RNA overlapping and
non-overlapping regions, respectively. The BLAST pro-
gram [54] was used to obtain the overlapping and non-
overlapping regions of each sense-antisense pair. Then,
the miRanda algorithm [55] was used for miRNA bind-
ing-site predictions. The numbers of predicted miRNAs
within sense-antisense pairing regions and non-pairing
regions were normalized to sequence length. Wilcoxon
two-sided test was computed in R to compare the differ-
ence in predicted miRNA binding sites within sense-anti-
sense pairing and non-pairing regions. In the
randomization test, all sequences derived from the pair-
ing and non-pairing regions were shuffled and sequences
were randomly selected to create two data sets to repre-
sent the simulated pairing and non-pairing region data,
respectively. The numbers of sequences included in the
simulated data sets were equal to those in the real data
sets. Wilcoxon two-sided test was used to compare the
predicted miRNAs between the simulated pairing and
non-paring data sets. The randomization procedure was
repeated 1,000 times. We calculated the number of times
(x) that the Wilcoxon P-value/W values in the random-
izations are smaller than those from the real data sets.
The P-value of the randomization is x/1,000. The statisti-
cally significant difference cut-off was 0.05.
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